Dyslipidemia Clinical Trial
Official title:
Effect of Administration of Capsaicin on Inflammatory Cytokines Profile(TNFα , IL - 1β , IL - 6, IL -8 , MIP - 1β) in Individuals With Dyslipidemia.
The increased mortality from cardiovascular disease has a significant impact on the
population, and the prevalence of these diseases it become one of the major problems, since
it is the leading cause of mortality and 1 in 3 Mexicans suffer from cardiovascular disease
according ENSANUT; the above is attributed to the increase of diseases associated with an
inflammatory process accelerated as obesity, dyslipidemia, hypertension (SAH) and diabetes
mellitus (DM).
The cholesterol is a major risk factor in the development of cardiovascular disease, and in
turn increases the chances of death; however, the treatment of choice is based on changes in
lifestyle, which for most people are difficult to maintain long-term. As for the drug
therapy treated with drugs many people do not achieve their therapeutic goals, and therefore
the inflammatory condition that underlies this disease remains.
Recent studies have focused on the possible role of capsaicin in the inflammatory state
through the agonistic effect it has on TRPV1. It has demonstrated the antiinflammatory
activity of capsaicin to enhance inflammation by free fatty acids (FFA) and reducing the
expression of certain genes involved in this process induced. Capsaicin is a natural choice
and well tolerated with few side effects limited to the gastrointestinal tract such as
dyspepsia and intestinal irregularity, for the above is of interest to evaluate the effect
of capsaicin on the profile of inflammatory cytokines in individuals with dyslipidemia.
It will conduct a clinicala trial, double - blind, randomized and placebo control group. Female and male patients, with dyslipidemia. Two groups will be formed with 17 patients each (capsaicin 150 mg per day or Magnesia calcinada). At the beginning and end of the intervention clinical and laboratory determination. The data obteined were analyzed using SPSS statistical software version 22. It was considered statistically significant at p <0.05 ;
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001154 -
Lipoprotein Metabolism in Normal Volunteers and Patients With High Levels of Lipoproteins
|
||
| Not yet recruiting |
NCT06405880 -
Pharmacist Case Finding and Intervention for Vascular Prevention Trial
|
N/A | |
| Recruiting |
NCT02837367 -
Use of Nutrigenomic Models for the Personalized Treatment With Medical Foods in Obese People
|
N/A | |
| Active, not recruiting |
NCT02600338 -
Meta-analyses of the Effect of Legumes on Blood Pressure
|
N/A | |
| Active, not recruiting |
NCT02223793 -
Vascular Lifestyle-Intervention and Screening in Pharmacy
|
N/A | |
| Completed |
NCT02163044 -
The Hellenic Postprandial Lipemia Study (HPLS)
|
||
| Recruiting |
NCT01972113 -
Vitamin K and Glucose Metabolism in Children at Risk for Diabetes (Vita-K 'n' Kids Study)
|
N/A | |
| Recruiting |
NCT01705873 -
Analysis on the Risk of Cardiovascular Events in HIV- Infected Subjects Treated With LPV/r Based HAART Regimen vs. an EFV Based Regimen
|
N/A | |
| Completed |
NCT01764295 -
Clinical Study for Patients With Hypertension Associated With Dyslipidemia
|
Phase 3 | |
| Terminated |
NCT01414166 -
Niacin/Laropiprant Tablet for South and Southeast Asians With Low High-Density Lipoprotein Cholesterol (LDL-C) at Risk for Cardiovascular Disease (MK-0524A-108)
|
Phase 3 | |
| Completed |
NCT01531062 -
Effect of Nigella Sativa on Lipid Profiles in Elderly
|
Phase 2 | |
| Completed |
NCT01990391 -
Brazil Nut Consumption in Microvascular Endothelial Function, Oxidative Stress and Metabolic Abnormalities
|
N/A | |
| Recruiting |
NCT01670968 -
HIV Reverse Cholesterol Transport Study
|
||
| Completed |
NCT00977288 -
A Study of Safety and Efficacy of MK0859 (Anacetrapib) in Japanese Patients With Dyslipidemia (0859-029)
|
Phase 2 | |
| Completed |
NCT01285544 -
The Efficacy and Tolerability of Two Formulations of Atorvastatin In Korean Adult With Hypercholesterolemia
|
Phase 4 | |
| Withdrawn |
NCT00664287 -
Extended Release (ER) Niacin/Laropiprant Add on Study (0524A-082)
|
Phase 3 | |
| Completed |
NCT00768274 -
Safety, Pharmacokinetic Study of RVX000222 in Healthy Subjects and Subjects With Low HDL Cholesterol
|
Phase 1/Phase 2 | |
| Completed |
NCT00300430 -
Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.
|
Phase 3 | |
| Completed |
NCT01483235 -
Reduced Cardiac Rehabilitation Program
|
N/A | |
| Completed |
NCT00143663 -
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
|
Phase 3 |